Indivior Pharmaceuticals, Inc. (SPUN)

Indivior Pharmaceuticals Revenue

Indivior Pharmaceuticals had revenue of $356.00M in the quarter ending September 30, 2026, with 13.38% growth. This brings the company's total for the last twelve months to $1.37B, up 16.44% year-over-year. In the year 2025, Indivior Pharmaceuticals had annual revenue of $1.24B with 4.29% growth.

• Revenue (ttm): $1.37B
• Revenue Growth: +16.44%
• P/S Ratio: 3.12
• Revenue / Employee: $1,639,618
• Employees: 838
• Market Cap: 4.28B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• United States 1.05B 85.0%
• Rest of World 186.00M 15.0%

Fiscal year ended Dec 31, 2025 See the full Indivior Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.24B	51.00M	4.29%
Dec 31, 2024	1.19B	95.00M	8.69%
Dec 31, 2023	1.09B	192.00M	21.31%
Dec 31, 2022	901.00M	110.00M	13.91%
Dec 31, 2021	791.00M	144.00M	22.26%
Dec 31, 2020	647.00M	-138.00M	-17.58%
Dec 31, 2019	785.00M	-220.00M	-21.89%
Dec 31, 2018	1.01B	-88.00M	-8.05%
Dec 31, 2017	1.09B	35.00M	3.31%
Dec 31, 2016	1.06B	44.00M	4.34%
Dec 31, 2015	1.01B	-101.00M	-9.06%
Dec 31, 2014	1.12B	-101.00M	-8.31%
Dec 31, 2013	1.22B	-123.00M	-9.19%
Dec 31, 2012	1.34B	85.00M	6.78%
Dec 31, 2011	1.25B	-	-

Data Sources: Fiscal.ai and S&P Global Market Intelligence Last updated: Sep 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company. Revenue geography data is provided by S&P Global Market Intelligence.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error